vs
Apellis Pharmaceuticals, Inc.（APLS）与LSI INDUSTRIES INC（LYTS）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是LSI INDUSTRIES INC的1.4倍（$199.9M vs $143.9M），LSI INDUSTRIES INC净利率更高（1.4% vs -29.5%，领先30.9%），LSI INDUSTRIES INC同比增速更快（-4.4% vs -5.9%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 2.1%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
LSI Logic Corporation是一家总部位于加利福尼亚州圣克拉拉的美国公司，主营专用集成电路与电子设计自动化业务，设计并销售可加速数据中心、移动网络及客户端计算领域存储与网络性能的半导体和软件产品。
APLS vs LYTS — 直观对比
营收规模更大
APLS
是对方的1.4倍
$143.9M
营收增速更快
LYTS
高出1.5%
-5.9%
净利率更高
LYTS
高出30.9%
-29.5%
两年增速更快
APLS
近两年复合增速
2.1%
损益表 — Q4 FY2025 vs Q1 FY2027
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $143.9M |
| 净利润 | $-59.0M | $2.0M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | 1.4% |
| 营收同比 | -5.9% | -4.4% |
| 净利润同比 | -62.2% | -4.8% |
| 每股收益（稀释后） | $-0.40 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSLYTS
| Q3 26 | — | $143.9M | ||
| Q1 26 | — | $143.9M | ||
| Q4 25 | $199.9M | $147.0M | ||
| Q3 25 | $458.6M | $157.2M | ||
| Q2 25 | $178.5M | $155.1M | ||
| Q1 25 | $166.8M | $132.5M | ||
| Q4 24 | $212.5M | $147.7M | ||
| Q3 24 | $196.8M | $138.1M |
净利润APLSLYTS
| Q3 26 | — | $2.0M | ||
| Q1 26 | — | $2.0M | ||
| Q4 25 | $-59.0M | $6.3M | ||
| Q3 25 | $215.7M | $7.3M | ||
| Q2 25 | $-42.2M | $8.2M | ||
| Q1 25 | $-92.2M | $3.9M | ||
| Q4 24 | $-36.4M | $5.6M | ||
| Q3 24 | $-57.4M | $6.7M |
毛利率APLSLYTS
| Q3 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | 25.5% | ||
| Q3 25 | — | 25.6% | ||
| Q2 25 | — | 26.1% | ||
| Q1 25 | — | 24.8% | ||
| Q4 24 | — | 23.6% | ||
| Q3 24 | — | 24.4% |
营业利润率APLSLYTS
| Q3 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | -25.6% | 6.0% | ||
| Q3 25 | 48.7% | 7.0% | ||
| Q2 25 | -18.6% | 7.7% | ||
| Q1 25 | -50.0% | 4.7% | ||
| Q4 24 | -12.3% | 5.7% | ||
| Q3 24 | -24.0% | 6.6% |
净利率APLSLYTS
| Q3 26 | — | 1.4% | ||
| Q1 26 | — | 1.4% | ||
| Q4 25 | -29.5% | 4.3% | ||
| Q3 25 | 47.0% | 4.6% | ||
| Q2 25 | -23.6% | 5.3% | ||
| Q1 25 | -55.3% | 2.9% | ||
| Q4 24 | -17.1% | 3.8% | ||
| Q3 24 | -29.2% | 4.8% |
每股收益（稀释后）APLSLYTS
| Q3 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $-0.40 | $0.20 | ||
| Q3 25 | $1.67 | $0.23 | ||
| Q2 25 | $-0.33 | $0.26 | ||
| Q1 25 | $-0.74 | $0.13 | ||
| Q4 24 | $-0.30 | $0.18 | ||
| Q3 24 | $-0.46 | $0.22 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | $261.0M |
| 股东权益账面价值 | $370.1M | $352.8M |
| 总资产 | $1.1B | $800.5M |
| 负债/权益比越低杠杆越低 | — | 0.74× |
8季度趋势，按日历期对齐
现金及短期投资APLSLYTS
| Q3 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $466.2M | $6.4M | ||
| Q3 25 | $479.2M | $7.1M | ||
| Q2 25 | $370.0M | $3.5M | ||
| Q1 25 | $358.4M | $4.3M | ||
| Q4 24 | $411.3M | $4.7M | ||
| Q3 24 | $396.9M | $7.0M |
总债务APLSLYTS
| Q3 26 | — | $261.0M | ||
| Q1 26 | — | $261.0M | ||
| Q4 25 | — | $27.9M | ||
| Q3 25 | — | $50.7M | ||
| Q2 25 | — | $48.6M | ||
| Q1 25 | — | $55.4M | ||
| Q4 24 | — | $38.2M | ||
| Q3 24 | — | $47.7M |
股东权益APLSLYTS
| Q3 26 | — | $352.8M | ||
| Q1 26 | — | $352.8M | ||
| Q4 25 | $370.1M | $248.1M | ||
| Q3 25 | $401.2M | $241.3M | ||
| Q2 25 | $156.3M | $230.7M | ||
| Q1 25 | $164.2M | $221.7M | ||
| Q4 24 | $228.5M | $217.1M | ||
| Q3 24 | $237.1M | $211.2M |
总资产APLSLYTS
| Q3 26 | — | $800.5M | ||
| Q1 26 | — | $800.5M | ||
| Q4 25 | $1.1B | $396.3M | ||
| Q3 25 | $1.1B | $404.9M | ||
| Q2 25 | $821.4M | $396.4M | ||
| Q1 25 | $807.3M | $384.6M | ||
| Q4 24 | $885.1M | $344.5M | ||
| Q3 24 | $901.9M | $349.5M |
负债/权益比APLSLYTS
| Q3 26 | — | 0.74× | ||
| Q1 26 | — | 0.74× | ||
| Q4 25 | — | 0.11× | ||
| Q3 25 | — | 0.21× | ||
| Q2 25 | — | 0.21× | ||
| Q1 25 | — | 0.25× | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | 0.23× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSLYTS
| Q3 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $25.0M | ||
| Q3 25 | $108.5M | $676.0K | ||
| Q2 25 | $4.4M | $9.5M | ||
| Q1 25 | $-53.4M | $6.9M | ||
| Q4 24 | $19.4M | $9.9M | ||
| Q3 24 | $34.1M | $11.8M |
自由现金流APLSLYTS
| Q3 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $23.3M | ||
| Q3 25 | $108.3M | $-291.0K | ||
| Q2 25 | $4.4M | $8.5M | ||
| Q1 25 | $-53.4M | $6.2M | ||
| Q4 24 | $19.3M | $8.8M | ||
| Q3 24 | — | $11.1M |
自由现金流率APLSLYTS
| Q3 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 15.8% | ||
| Q3 25 | 23.6% | -0.2% | ||
| Q2 25 | 2.5% | 5.5% | ||
| Q1 25 | -32.0% | 4.7% | ||
| Q4 24 | 9.1% | 6.0% | ||
| Q3 24 | — | 8.0% |
资本支出强度APLSLYTS
| Q3 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 1.1% | ||
| Q3 25 | 0.0% | 0.6% | ||
| Q2 25 | 0.0% | 0.6% | ||
| Q1 25 | 0.0% | 0.5% | ||
| Q4 24 | 0.0% | 0.7% | ||
| Q3 24 | 0.0% | 0.5% |
现金转化率APLSLYTS
| Q3 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | 3.94× | ||
| Q3 25 | 0.50× | 0.09× | ||
| Q2 25 | — | 1.16× | ||
| Q1 25 | — | 1.77× | ||
| Q4 24 | — | 1.75× | ||
| Q3 24 | — | 1.77× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
LYTS
暂无分部数据
